The most common prescription drugs you pick up at the pharmacy counter or fill via mail order will likely get more expensive under President Donald Trump's plan to assess a 100% tariff on imported ...

Imported generic drugs will face a 100 percent tariff beginning in August 2028 unless manufacturers move production to the U.S., President Trump said in a social media post Tuesday. Trump wrote on ...

Trump plans tariffs of up to 200% on imported generic drugs after a two-year grace period aimed at encouraging U.S. manufacturing. But thin profit margins make tariffs harder to absorb than for ...

While the White House focused its initial Section 232 pharmaceutical tariffs on branded drugs, generics makers—who supply the vast majority of U.S. prescriptions—won’t stay in the clear for long. In ...

President Donald Trump announced Tuesday that imported generic drugs will remain tariff-free for the next two years before facing steep new import duties, saying the move is designed to encourage ...

A multiyear “tariff cliff” sets 0% through July 2028, then 100% for one year and 200% thereafter, explicitly tying penalties to failure to establish US manufacturing capacity. Sparse implementation ...

South Africa’s health regulator ⁠is reviewing 12 applications for generic versions of semaglutide, the active ingredient in Novo Nordisk’s blockbuster diabetes and weight-loss medicines, it said on ...

The administration has repeatedly said it will impose steep pharmaceutical tariffs but has not followed through on them. By Rebecca Robbins President Trump said on Tuesday evening that he planned to ...

President Donald Trump on Tuesday announced a plan to impose a 100 percent tariff on generic drugs starting in August 2028 as part of a bid to push pharmaceutical production back to the United States.

The Hikma Court correctly held that a generic manufacturer should not be liable for induced patent infringement if it carves patented uses out of its label. FDA can navigate Hikma’s aftermath without ...

Share on Pinterest Federal regulators have agreed to review a Swiss pharmaceutical company’s applications for two cheaper generic versions of Zepbound and Mounjaro. MK Photo/Alamy Stock Photo Federal ...

Jessica Rendall is a reporter with experience covering a variety of health and wellness topics, including chronic disease, infectious disease, telemedicine, mental health and health technology. Carley ...